Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ulrich J M, Mey"'
Autor:
Jeroen S. Goede, Christa K. Baumann, Richard Cathomas, Nina Khanna, Jean-Francois Lambert, Thomas Lehmann, Ulrich J. M. Mey, Jörg Seebach, Urs C. Steiner, Astrid Tschan-Plessl, Frank Stenner
Publikováno v:
Swiss Medical Weekly, Vol 154, Iss 9 (2024)
Immunoglobulins for intravenous use (IVIgs) and subcutaneous use (SCIgs) can prevent recurrent and severe infections in patients with secondary antibody deficiencies that are frequently linked to haematological/oncological malignancies as well as oth
Externí odkaz:
https://doaj.org/article/8740b918b44a46adbecb48308fcd8252
Autor:
Murielle Lalive d’Epinay, Sabine Güsewell, Nicole Graf, Ulrich J. M. Mey, Christoph Driessen, Felicitas Hitz
Publikováno v:
Hematological Oncology. 40:716-723
Major improvements in outcome of older patients with multiple myeloma (MM) have been achieved with the introduction of novel agents. Their impact in real-life treatment of older patients is unclear. In this single center retrospective study, we analy
Autor:
Ulrich J. M. Mey, Felicitas Hitz, Andreas Lohri, Stefanie Pederiva, Christian Taverna, Alexander Tzankov, Oliver Meier, Karen Yeow, Christoph Renner
Publikováno v:
Swiss Medical Weekly, Vol 142, Iss 0506 (2012)
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens,
Externí odkaz:
https://doaj.org/article/60c2c513282e46599040739cecb8864b
Autor:
Ulrich J M, Mey, Wolfram, Brugger, Heike, Schwarb, Stefanie, Pederiva, Andreas, Schwarzer, Tobias, Dechow, Paul, Jehner, Jacqueline, Rauh, Christian J, Taverna, Mathias, Schmid, Martin, Schmidt-Hieber, Steffen, Doerfel, Natalie, Fischer, Axel, Ruefer, Carsten, Ziske, Wolfgang, Knauf, Richard, Cathomas, Roger, von Moos, Felicitas, Hitz, Rafael, Sauter, Elke, Hiendlmeyer, Nathan, Cantoni, Mario, Bargetzi, Christoph, Driessen
Publikováno v:
British journal of haematology. 176(5)
The combination of lenalidomide (Revlimid
Autor:
Ulrich J. M. Mey
Publikováno v:
Therapeutische Umschau. 67:527-535
Die Therapiemöglichkeiten des Multiplen Myeloms haben sich in den vergangenen Jahren erheblich verbessert. Die Verfügbarkeit neuer Substanzen – insbesondere Thalidomid, Bortezomib (Velcade®) und Lenalidomid (Revlimid®) – hat die Behandlungsop
Autor:
Ulrich J M, Mey, Christoph, Leitner, Christoph, Driessen, Richard, Cathomas, Dirk, Klingbiel, Felicitas, Hitz
Publikováno v:
Hematological oncology. 34(4)
Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only
Autor:
Ulrich J. M. Mey
Publikováno v:
Therapeutische Umschau. :0126-0126